drugset / Trial / NCT00871000

Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.

NCT00871000

Phase 3 Completed 303 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

This phase 3b study will compare the immunogenicity and reactogenicity of the dTpa-IPV vaccine to that of a DTPa-IPV vaccine when administered as a booster dose in healthy children 5-6 years of age who have received three primary vaccination doses of DTPa-based vaccine according to the "3-5-11" month schedule recommended in Italy. In this study, MMRV vaccine will also be co-administered to all children.

Timeline

Start
2009-04-01
Primary completion
2009-11-18
Completion
2009-11-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Boostrix Polio Vaccine Intramuscular
Comparator Tetravac Vaccine Intramuscular
Background Priorix-Tetra Vaccine Subcutaneous